EPHA2 and neoplasm: In BL-0293 and BL-0382 tumor models, shorter survival was not only attributed to tumor regrowth, but was driven by unexplained weight loss, possibly caused by the metastatic progression that was mainly seen in the DTX treated group and partially seen in the EphA2-ILs-DTXp group (Figure 3D).